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Abstract
To define potentially causal variants for autoimmune disease, we fine-mapped1,2 76 rheumatoid 
arthritis (11,475 cases, 15,870 controls)3 and type 1 diabetes loci (9,334 cases, 11,111 controls)4. 
After sequencing 799 1-kilobase regulatory (H3K4me3) regions within these loci in 568 
individuals, we observed accurate imputation for 89% of common variants. We defined credible 
sets of ≤5 causal variants at 5 rheumatoid arthritis and 10 type 1 diabetes loci. We identified 
potentially causal missense variants at DNASE1L3, PTPN22, SH2B3, and TYK2, and noncoding 
variants at MEG3, CD28-CTLA4, and IL2RA. We also identified potential candidate causal 
variants at SIRPG and TNFAIP3. Using functional assays, we confirmed allele-specific protein 
binding and differential enhancer activity for three variants: the CD28-CTLA4 rs117701653 SNP, 
MEG3 rs34552516 indel, and TNFAIP3 rs35926684 indel.
Rheumatoid arthritis is an autoimmune disease with citrullinated peptide reactivity where 
chronic inflammation leads to joint destruction5. Type 1 diabetes (T1D) arises through 
autoimmune reactivity to proinsulin6 and glutamic acid decarboxylase7, leading to 
destruction of pancreatic β cells and loss of insulin production. Genome-wide association 
studies have identified 101 rheumatoid arthritis loci3,8 and 53 T1D loci4; these alleles 
implicate CD4+ T-cell function in autoimmunity9–11. However, causal variants for most loci 
have yet to be defined. Pinpointing them will enable mechanistic investigation to identify the 
specific genes, regulatory structures, and genetic mechanisms central to autoimmunity.
Bayesian fine-mapping has been successfully applied to prioritize associated variants in 
complex diseases1,12–14. We fine-mapped 76 autosomal non-major-histocompatibility-
complex loci in rheumatoid arthritis (11,475 cases, 15,870 controls)3 and T1D (9,334 cases, 
11,111 controls) (Supplementary Table 1)4, covering 46 and 49 loci with known rheumatoid 
arthritis and T1D associations, respectively (Supplementary Table 2). To enable accurate 
comprehensive imputation, we used individuals genotyped on ImmunoChip, with dense SNP 
coverage in selected autoimmune disease loci. Our sample size is smaller than the largest of 
previously published association analyses4,8. However, Okada et al.8 used imputed 
genotypes but did not define credible sets, and while Onengut-Gumuscu et al.4 determined 
credible sets, they did not use imputation so their study included fewer than half of the 
variants assessed here. We fine-mapped rheumatoid arthritis and T1D together since 
potential causal variants for both diseases overlap functional elements in CD4+ T cells11.
Since fine-mapping methods are highly sensitive to missing data, we benchmarked different 
imputation strategies. After sequencing 799 1-kilobase regulatory (H3K4me3) regions in 
568 individuals within these loci, we observed that the 1000 Genomes cosmopolitan 
reference panel yielded the best results (Fig. 1), while indels and multi-allelic variants 
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remain challenging to impute (Supplementary Note, Supplementary Tables 3–7, and 
Supplementary Figs. 1–4).
After imputation, we calculated association statistics for 66,923 variants for rheumatoid 
arthritis and 66,942 variants for T1D (minor allele frequency (MAF) > 1%, imputation 
quality score (INFO) > 0.3; Hardy–Weinberg P > 10−5) at 76 loci. In rheumatoid arthritis 
and T1D, respectively, we identified 20 and 34 significant loci (P < 7.5 × 10−7), mostly 
consistent with previous studies (Supplementary Note and Supplementary Table 8). Using 
approximate Bayesian fine-mapping, we assigned posterior probabilities and defined a 95% 
credible set for each locus1,2.
Seven loci were significantly associated with both diseases (PTPN22, AFF3, CD28-CTLA4, 
BACH2, RASGRP1, PTPN2, and TYK2). Rheumatoid arthritis and T1D variant effect sizes 
were positively correlated in 64% of the tested loci (Methods, Supplementary Table 9, and 
Supplementary Fig. 5), suggesting shared signals. To prioritize possible shared causal 
variants, we analyzed a combined dataset (20,787 rheumatoid arthritis or T1D cases, and 
18,616 controls; Methods) and observed significant associations at 28 loci. Most (62%) 
associated variants in these loci were in linkage disequilibrium with the strongest associated 
variant in either rheumatoid arthritis or T1D (coefficient of determination (R2) > 0.8; 
Supplementary Table 10). The combined analysis indicated a potential shared signal at the 
PRKCQ locus (Supplementary Note) that was not significant in rheumatoid arthritis or T1D 
alone. We did not identify additional significant loci. We did not observe residual population 
stratification by combining both datasets (Supplementary Note, Supplementary Table 11, 
and Supplementary Fig. 6). Multinomial Bayesian fine-mapping accounting for opposing 
effects15 did not identify additional loci (Supplementary Note and Supplementary Table 12). 
Because six out of seven shared loci had smaller credible sets in the combined analysis than 
for the individual disease analyses (Supplementary Note), we decided to use the combined 
analysis for those six loci.
We narrowed down the list of probable causal variants to ≥5 in 5 out of 20 significant 
rheumatoid arthritis loci and 10 out of 34 significant T1D loci. We subsequently limited the 
analysis to 9 (rheumatoid arthritis), 14 (T1D), and 11 (combined) loci with ≤10 variants in 
the credible sets (Fig. 2a,b and Supplementary Table 13). Credible sets for these loci were 
not markedly altered when considering variants unique to the Haplotype Reference 
Consortium (HRC) reference panel (Supplementary Fig. 7 and Supplementary Table 14). To 
systematically investigate candidate causal variants for both diseases, we selected those with 
a posterior probability of >0.2 (Table 1). We considered variants to be potentially causal if 
they: (1) were a missense coding variant; or (2) were in a region with evidence of enhancer 
activity, and demonstrated allele-specific binding in electrophoretic mobility shift assays 
(EMSAs) and allele-specific enhancer function in luciferase assays (Supplementary Table 
15). Approximate Bayesian fine-mapping assumes a single causal variant per locus, although 
multiple independent causal variants may be present. Therefore, we applied conditional 
analysis, exhaustive testing of all variant pairs, FINEMAP16 (which assumes multiple 
variants), and haplotype analysis for regions where there was evidence of a secondary effect 
(P < 1.9 × 10−5).
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We identified 42 variants at 20 loci with a posterior probability of >0.2 (Table 1), including 5 
missense variants (PTPN22, DNASE1L3, SH2B3, TYK2, and SIRPG), 3 indels 
(ANKRD55, TNFAIP3, and MEG3), and 34 noncoding SNP variants (PTPN22, IL10, 
IFIH1, CD28-CTLA4, ANKRD55, BACH2, CCL21, IL2RA, INS, SH2B3, Chr13, MEG3, 
CTSH, TYK2, SIRPG, UBASH3A, and C1QTNF6). We observed a 16-fold posterior 
probability enrichment for missense variants. Potentially causal missense variants at 
PTPN22, SH2B3, and TYK2 are well described in the literature4,17–19 (Supplementary Note 
and Supplementary Figs. 8–10). We also noted potentially causal missense variants in 
DNASE1L3 and SIRPG.
DNASE1L3 encodes a nuclease that cleaves double-stranded DNA during apoptosis20. The 
3p14 DNASE1L3 locus confers rheumatoid arthritis susceptibility without evidence of a 
T1D effect (P > 0.02; Supplementary Fig. 11). The reported3 lead SNP rs35677470, 
encoding an p.Arg206Cys change in DNASE1L3, has a high posterior probability (P = 1.8 × 
10−8; posterior probability = 0.82; Supplementary Table 13) and is in linkage disequilibrium 
with another reported8 lead variant, rs73081554 (R2 = 0.79). Conditioning on p.Arg206Cys 
obviates any evidence of independent risk variants (P > 5 × 10−4; Supplementary Table 16). 
p.Arg206Cys has been implicated in systemic sclerosis21; other loss-of-function DNASE1L3 
mutations have been reported in familial forms of systemic lupus erythematosus22. 
p.Arg206Cys is a loss-of-function variant that abolishes the protein’s nuclease activity23.
Within 20p13, we identified a p.Val263Ala signal-regulatory protein gamma (SIRPG) 
missense variant with modest posterior probability (rs6043409; P = 3.9 × 10−10; posterior 
probability = 0.24) for T1D (Supplementary Fig. 12 and Supplementary Table 13). 
Conditional analysis using rs6043409 obviated any association signal in the locus (P > 2 × 
10−3). p.Val263Ala is in the D3 domain24. While D3 has unknown function, homologous D1 
and D2 immunoglobulin-like domains mediate interaction with CD47 ligands and SIRPG 
dimerization25–27. We observed linkage disequilibrium (R2 > 0.8) with protein quantitative 
trait loci (QTL) and expression QTL (eQTL) SNPs (Supplementary Table 17), suggesting 
that p.Val263Ala might cause a SIRPG conformational change that alters stability, structure, 
or function. Since p.Val263Ala has unknown function, the two noncoding variants in the 
SIRPG credible set with comparable posterior probabilities and regulatory effects may 
potentially be causal. However, given the enrichment of missense variants in our data and 
elsewhere28,29, we consider p.Val263Ala as the strongest candidate causal variant at this 
locus.
We identified noncoding alleles with allele-specific function at CTLA4–CD28, TNFAIP3, 
and MEG3 in regions with evidence of CD4+ T-cell enhancer function (Table 1). We 
identified the rs61839660 variant at IL2RA with a high posterior probability (0.85), which 
was recently demonstrated to have allele-specific regulatory and cellular functions 
confirmed by CRISPR assays30. Detailed analyses of all other loci with ≥10 variants in the 
95% credible set are presented in the Supplementary Note and Supplementary Figs. 13–24.
CD28 and CTLA4 are central to the regulation and differentiation of T cells20. The 2q33.2 
CD28–CTLA4 locus is shared by rheumatoid arthritis and T1D31. In the combined analysis, 
a single variant had a high posterior probability (rs3087243; P = 1.4 × 10−16; posterior 
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probability = 0.91) near CTLA4, which also has the largest posterior probability in T1D (P = 
1.6 × 10−15; posterior probability = 0.48; Fig. 3a, Supplementary Fig. 25a, and 
Supplementary Table 13), but not in rheumatoid arthritis (P = 1.6 ×10−8; posterior 
probability = 0.02). Incontrast,rs117701653nearCD28 (R2 = 0.03 with rs3087243) carried 
the highest posterior probability in rheumatoid arthritis (P = 3.5 ×10−10; posterior 
probability = 0.67). In conditional analysis on rs3087243, rs117701653 demonstrated an 
independent effect (P = 4.0 × 10−8; Fig. 3a and Supplementary Table 16). The FINEMAP16 
program identified the rs117701653 + rs3087243 pair as having the highest posterior 
probability (0.05; Supplementary Table 18), consistent with an analysis where we tested all 
SNP pairs exhaustively in rheumatoid arthritis (Fig. 3b and Supplementary Fig. 25b). 
Haplotype analysis demonstrated independent protective effects of rs3087243-A and 
rs117701653-C alleles in rheumatoid arthritis and T1D (Fig. 3c), suggesting that 
rs117701653 might similarly influence T1D risk (P = 0.03 in the conditional haplotype 
analysis). A previous association study identified rs1980422 as the variant with the strongest 
association in the CD28 region8 (R2 = 0.02 with rs117701653 and R2 = 0.04 with 
rs3087243). Haplotype analysis indicated that rs1980422 imperfectly tags high-frequency 
haplotypes defined by rs3087243 and rs117701653 (Supplementary Fig. 25c). Both 
rs117701653 and rs3087243 overlap H3K4me3 peaks in immune cells and disrupt protein-
binding motifs (Supplementary Tables 19–25 and Supplementary Note). Only rs3087243 
was in linkage disequilibrium with an eQTL (CTLA4 in CD4+ and CD8+ cells and testis; R2 
> 0.8; Supplementary Table 17).
We observed allele-specific protein binding and enhancer activity for rs117701653, but not 
rs3087243 (Fig. 3d). The rs117701653-C allele showed higher specific binding than the A 
allele in Jurkat T-cell nuclear extracts by EMSA (Supplementary Fig. 25d) and conferred 
higher luciferase expression (P = 0.0017; Fig. 3e). The binding is lineage specific: it was 
absent in THP-1 monocytic cells (Supplementary Fig. 25d). We observed peak overlap in an 
assay for transposase-accessible chromatin sequencing (ATAC-Seq) for rs117701653 in 
CD4+ T cells (Supplementary Table 25) and a subtle increase in luciferase expression with 
the C allele after anti-CD3/CD28 cell stimulation (P = 0.02; Supplementary Fig. 25e), 
suggesting that binding may be stimulation dependent. While the rheumatoid arthritis 
credible set variant rs55686954 (R2 = 0.91 with rs117701653, posterior probability = 0.27) 
showed allele-specific protein binding, it had no evidence of allele-specific enhancer 
function (Supplementary Fig. 25d,e). Promoter-capture Hi-C assays32 demonstrated 
genomic contacts between the rs117701653 region and the CTLA4 promoter and a region 
downstream of RAPH1 (Supplementary Fig. 26), suggesting that, despite its proximity to 
CD28, the allele may influence CTLA4 or RAPH1 gene regulation.
MEG3 is a noncoding RNA tumor suppressor gene whose transcript binds p53 (ref. 33). 
Paternal alleles carry greater risk34 in this 14q32.2 T1D locus. It shows no association to 
rheumatoid arthritis (P > 0.04). Two variants with >0.2 probabilities in the credible set were 
the rs34552516 indel (P = 1.1 × 10−9; posterior probability = 0.42) and rs56994090 intronic 
variant (P = 1.1 × 10−9; posterior probability = 0.44; linkage disequilibrium with 
rs34552516, R2 = 0.99; Fig. 4a, Supplementary Fig. 27a, and Supplementary Table 12). 
While we observed no evidence of independent variants conditioning on rs34552516 (P > 
0.04; Supplementary Table 13), FINEMAP analysis could not exclude the possibility of a 
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secondary association (Supplementary Table 18 and Supplementary Note). Both MEG3 
variants overlap DNAse-I hypersensitive sites (DHS) and H3K4me3 regions in multiple cell 
types (Supplementary Tables 20 and 21), but do not overlap ATAC-Seq peaks after 
stimulation (Supplementary Table 25) and are not in high linkage disequilibrium (R2 > 0.8) 
with QTL SNPs.
We observed that the rs34552516-TC allele demonstrated specific Jurkat cell nuclear extract 
binding (Fig. 4b) and increased luciferase activity compared with empty vector (P = 0.01) 
and the T allele (P < 0.05; Fig. 5c). We observed no specific binding in THP-1 cells 
(Supplementary Fig. 27b), indicating cell-type specificity. In contrast, we observed no allele-
specific binding for rs56994090 (Fig. 4b). The region harboring rs34552516 in promoter-
capture Hi-C data32 showed contacts to DIO3 and RP11–1029J19 promoters 
(Supplementary Fig. 26), suggesting multiple downstream genes. We favor rs34552516 as 
potentially causal based on our functional evidence, but acknowledge that these assays are 
limited and cannot exclude rs56994090 function that may occur in other unexamined 
cellular contexts.
The 6q23.3 TNFAIP3 gene encodes A20, which inhibits nuclear factor-κB signaling and 
prevents apoptosis20. It is associated with multiple autoimmune diseases35–41, including 
rheumatoid arthritis, but not T1D (P > 2.3 × 10—4). The indel rs35926684 carries the highest 
posterior probability (P = 6.5 × 10—12; posterior probability = 0.24; Fig. 5a, Supplementary 
Table 13, and Supplementary Fig. 28a) of 9 variants in the credible set and is in linkage 
disequilibrium with the previously identified SNPs rs17264332 (R2 = 0.86)8 and rs6920220 
(R2 = 0.88)3. Conditional analysis identified independent association at rs58721818 (P = 3.6 
×10−5; R2 = 0.05 with rs35926684; Fig. 5a and Supplementary Table 16). A previous study3 
identified secondary signals at rs5029937 (linked to rs58721818; R2 = 0.84) and 
rs13207033. Exhaustive pairwise analysis demonstrated comparable association for the 
rs35926684 + rs58721818 pair (−log10[P] = 13.95) and the most strongly associated 
rs6920220 + rs58721818 pair (−log10[P] = 14.21; Fig. 5b and Supplementary Fig. 28b). 
Haplotypes with the rs35926684-G allele increased rheumatoid arthritis risk, even in 
absence of the highly linked rs6920220-A risk allele (that is, GGGC versus GAGC; Fig. 5c), 
although this effect was not significant in conditional haplotype analysis (P = 0.14). 
Consistent with our exhaustive pairwise search, FINEMAP identified the rs35926684 + 
rs58721818 combination as having the thirteenth highest posterior probability 
(Supplementary Table 18).
The rs35926684 indel alters binding motifs, overlaps enhancer marks and Encyclopedia of 
DNA Elements transcription factor binding site (TFBS) chromatin immunoprecipitation 
sequencing peaks in immune cell types (Supplementary Note and Supplementary Tables 20, 
21, and 23–25), and is in linkage disequilibrium (R2 > 0.8) with a methylation QTL in 
neutrophils (Supplementary Table 17). EMSA identified stronger specific binding of Jurkat-
cell nuclear extract for the rs35926684-GA allele than the G allele (Fig. 5d and 
Supplementary Fig. 28c). Luciferase assays demonstrated increased enhancer activity with 
the GA allele compared with the empty vector (P = 7 × 10−4) and G allele (P = 0.053; Fig. 
5e). We observed no specific binding in THP-1 cells, indicating cell-type specificity 
(Supplementary Fig. 28c). We observed no allele-specific binding for rs6920220 
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(Supplementary Fig. 28c) or the other four alleles in partial linkage disequilibrium with 
rs35926684 (Posterior probability > 0.1), except for rs62432712. We did not observe allele-
specific enhancer activity for rs62432712 (Supplementary Fig. 28d). Hence, for this locus, 
we favor rs35926684 as the potentially causal variant since it has the best evidence of allele-
specific activity. Nevertheless, the presence of multiple alleles in linkage disequilibrium (R2 
> 0.86) provides ambiguity at this locus. Interestingly, in promoter-capture Hi-C data, the 
rs35926684 region contacts the TNFAIP3 promoter42 and the IL22RA and IFNGR1 
promoters (Supplementary Fig. 26)32, suggesting that multiple genes may be influenced by 
this rheumatoid arthritis risk allele.
Our study illustrates some challenges of fine-mapping. First, only a few loci had ≤10 
plausible causal variants, and in even fewer was it possible to identify promising candidates. 
Nonetheless, identifying plausible candidates in even a few instances is valuable. Second, 
we identified multiple potentially causal variants that were indels. Indels are the most likely 
to be missed or poorly imputed by current imputation reference panels (Supplementary 
Note), although coverage could improve with more complete reference panels based on 
high-depth whole-genome sequencing data. Third, since most loci have many plausible 
variants with low posterior probabilities, strategies to accurately predict causal variation 
from functional annotations are critical. This will require more precise noncoding maps that 
define regulatory elements central to the functions of pathogenic cell types.
We used a posterior probability of >0.2 to prioritize variants for functional follow-up, which 
allowed us to include variants that might have been excluded by fluctuations in calculated 
probabilities caused by quality control, genotyping error, imputation quality, and parameter 
choices. This threshold is relatively stringent (only 42 variants passed it in our entire study), 
and variants with a posterior probability of <0.2 may also be worthy of further investigation. 
We focused on loci with ≤10 variants in the 95% credible set; 12 loci had >10 variants in the 
95% credible set and at least 1 variant with a posterior probability of >0.2 (Supplementary 
Table 26). In the RASGRP1 and PRKQC credible sets, we observed a single variant with 
tenfold higher posterior probability than the remaining variants, but we did not investigate 
these loci in detail since they had weaker association and their credible set size suggests 
extensive linkage disequilibrium, making determination of the functional impact more 
difficult.
We used Jurkat T-cell lines for EMSA and luciferase assays since T cells are critical to the 
genetic etiology of rheumatoid arthritis and T1D. We acknowledge that, in vivo, many 
contexts may be relevant, some of which may not be captured by these assays. 
Consequently, many of the remaining variants with a posterior probability of >0.2 are 
plausible candidates that cannot be ruled out. Furthermore, our study is limited in identifying 
causal molecular mechanisms and genes. First, variants may be linked to multiple genes. For 
example, the region harboring the rs117701653 variant shows chromatin contacts with the 
CTLA4 promoter and the RAPH1 gene. Second, only a limited number of prioritized 
variants were in linkage disequilibrium with different molecular QTLs. As such, the specific 
gene(s) accounting for disease susceptibility remain(s) to be determined. Despite these 
limitations, we believe that the combination of statistical evidence with functional follow-up 
is a powerful way to prioritize potentially causal variants. Defining cellular models that best 
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represent the pathogenic cellular contexts is an essential component for this functional 
follow-up.
Methods
Ethics.
This study complies with all relevant ethical regulations. The study protocol was approved 
as an exempt study by Brigham and Women’s Hospital. Institutional Review Board approval 
for the original genotyping studies is described separately3,4.
Patient collections.
We used genotyping data from samples collected on the ImmunoChip platform 
(Supplementary Table 1)3,4. For rheumatoid arthritis, we used data for 11,475 cases and 
15,870 controls from 6 different cohorts (from the UK, the Swedish Epidemiological 
Investigation of Reumatoid Arthritis, the USA, the Netherlands, Umeå (Sweden), and 
Spain)3. For T1D, we used data for 12,241 cases and 14,636 controls from 2 different 
cohorts4: the Type 1 Diabetes Genetics Consortium (T1DGC) family collection, and the UK 
Genetic Resource Investigating Diabetes (GRID), British 1958 Birth Cohort, and UK Blood 
Service collection. To include trios from the Type 1 Diabetes Genetics Consortium cohort in 
the case-control analysis, we generated pseudocontrol pairs for each affected individual 
using the untransmitted alleles from the parents of that individual. As a consequence, the 
final numbers of individuals for T1D were 9,334 cases and 11,111 controls (including 1,661 
pseudocontrols). Genotype quality control was performed as described in the previously 
published studies. Additionally, we merged the genotype data for the different cohorts within 
T1D and rheumatoid arthritis using PLINK43, and converted genomic coordinates using the 
University of California, Santa Cruz liftOver tool44 and the hg18ToHg19 chain file. Variants 
unable to liftOver were removed. We then replaced the variant identifiers using National 
Center for Biotechnology Information Database of Single Nucleotide Polymorphisms 
(dbSNP) build 13845. Finally, we removed variants with a MAF of <0.5%.
Imputation.
To assess the imputation strategy best suited for fine-mapping, we tested three reference 
panels: (1) the European subpopulation of 1000 Genomes (n = 503); (2) the cosmopolitan 
panel of 1000 Genomes (n = 2,504); and (3) the HRC version 1.1 reference panel (n = 
32,611). We matched variants to each reference panel, removed variants absent in the 
reference panel, and aligned the strands of the remaining ImmunoChip genotypes. We 
extended the disease loci upstream and downstream by 1 Mb. We excluded variants when 
alleles could not be matched. For C/G and A/T variants, we removed the variant when the 
minor allele was unequal and the MAF was <45%. For multi-allelic variants, we ensured 
that the allele encoding was identical to the reference panel variant. This resulted in a 
different number of input variants for each imputation strategy (Supplementary Table 6). We 
imputed genotypes into rheumatoid arthritis and T1D separately. We phased and imputed the 
1000 Genomes reference panels using Beagle version 4.1 (22Apr16.1cf)46. To accommodate 
computational constraints of Beagle, we split the rheumatoid arthritis and T1D datasets into 
30 batches, randomizing cases and controls between batches, while maintaining trio 
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structure in the T1D dataset. Since the HRC version 1.1 reference panel genotype data are 
not publicly available, we evaluated different imputation servers and settings for the T1D 
dataset, to determine their effects on imputation output. On the Sanger Institute imputation 
server (date of access: 11 May 2016), we used prephasing with either EAGLE (version 
2.3.4)47 or SHAPEIT (version 2.r837)48, followed by imputation with PBWT (version 
3.0)49. On the Michigan University server (date of access: 5 July 2016), we split the dataset 
into three batches and used prephasing with EAGLE47 and imputation by MiniMac50. For 
rheumatoid arthritis, we performed HRC imputation on the Sanger imputation server using 
EAGLE prephasing followed by PBWT imputation. Finally, we locally performed 1000 
Genomes imputation by first phasing with EAGLE, and subsequently imputing using 
PBWT. We then merged the imputed dosages and probabilities from each batch (if any) for 
each imputation reference panel and replaced the variant identifiers in the imputed output 
using National Center for Biotechnology Information dbSNP build 138. We replaced 
genotypes for variants genotyped on ImmunoChip with the original genotypes. Genotyped 
variants correlated with genotypes after imputation (R2 > 0.99). Finally, we recalculated the 
imputation quality scores for each imputed variant in each dataset: we used the INFO score 
for biallelic variants and Beagle version 4.1 allelic-R2 for multi-allelic variants.
Targeted sequencing.
To test the accuracy of imputation, we sequenced 900 regions of 1,000 base pairs (bp) 
around H3K4me3 peak centers overlapping loci associated with either disease in 864 
individuals: 384 unrelated rheumatoid arthritis and 480 T1D individuals (160 trios), of 
which 149 and 480 were on ImmunoChip, respectively. We generated 100-bp paired-end 
reads with the Illumina MiSeq platform. Sequencing was performed at The Feinstein 
Institute for Medical Research at Northwell Health, and at The Center for Public Health 
Genomics, at the University of Virginia. We used BWA-mem51 (version 0.7.12) to align 
reads to the hg19 reference genome. We tagged and removed duplicate reads using Picard 
MarkDuplicates. We removed 101 regions where >50% of the samples had <20× coverage at 
>80% of sequenced bases, and removed 86 samples having <20× coverage at 90% of 
sequenced bases. We called genotypes using GATK version 3.4, following the recommended 
guidelines for using HaplotypeCaller52 in a joint genotype-calling approach. To determine 
the impact of local alignment on indel calls, we also called variants using the 
UnifiedGenotyper present in GATK. We then set genotypes with <10× coverage and 
genotype quality (QUAL) <30 to missing, and excluded variants with >5% missingness. We 
correlated called genotypes with ImmunoChip genotypes to identify and remove (when the 
coefficient of correlation (r) < 0.95) possible sample swaps and mismatched samples, 
resulting in 568 final samples (439 for T1D and 129 for rheumatoid arthritis). Finally, we 
selected variants with MAF > 1%, resulting in 1,862 variants within the 76 rheumatoid 
arthritis- and T1D-associated regions.
Combined dataset.
Before the association analysis, we merged the data for the rheumatoid arthritis and T1D 
dataset, imputed with the cosmopolitan reference panel of 1000 genomes. We identified 
shared controls between datasets by generating a list of linkage disequilibrium pruned 
variants from the ImmunoChip genotypes using PLINK43 (using --indep-pairwise 1000 100 
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0.2) and then used this list to determine the genetic similarity (unified additive 
relationship)53 between each pair of samples across both datasets. We considered sample 
pairs with a unified additive relationship of >0.2 genetically related, and randomly selected 
one sample of the pair to be included. We considered the remaining sample pairs unrelated. 
We finally merged genotypes and imputation probabilities from the selected samples and 
recalculated the imputation INFO scores for the merged genotypes as described earlier.
Fine-mapping and statistical analysis.
We limited our association analysis to variants with an overall MAF of >1%, a Hardy-
Weinberg P value of > 10−5 in controls, and an overall INFO score >0.3. The Hardy–
Weinberg P value was calculated using an exact test for biallelic variants and a Pearson’s 
chi-squared test for multi-allelic variants. We then split multi-allelic variants, creating a 
single variant for each alternative allele. To test each variant for association with disease, we 
used logistic regression, assuming a log-linear relation between the number of alternative 
alleles and case-control status. In the rheumatoid arthritis dataset, the null model included 
the first ten principal components calculated over the genotype covariance matrix, as 
described previously3, and five additional covariates indicating the cohort. For T1D, we 
included 12 regional indicator variables in the null model, as described previously4, and an 
additional variable indicating the cohort. For the joint analysis, the null model included all 
covariates for the T1D and rheumatoid arthritis datasets and an additional covariate 
indicating the sample originating dataset. We recoded the imputation probabilities to a 
dosage value ranging between 0 and 2 (that is P(AB) + 2 × P(BB)). Finally, we calculated 
the P value for the association as the difference in deviance between the null model and 
alternative model containing the imputation probabilities, which follows a chi-squared 
distribution with one degree of freedom. We corrected for multiple testing using a study-
wide Bonferroni threshold using the maximum number of tests across datasets (P < 7.5 × 
10−5 ∼ 0.05/67,156). To test whether our model was properly adjusting for population 
stratification when performing the combined analysis, we also evaluated using the first 20 
principal components as covariates. We obtained principal components with the PLINK43 –
pca command using the non-imputed and pruned combined ImmunoChip genotypes. By also 
including a covariate indicating the source dataset of each individual, we accounted for any 
residual technical differences caused by rheumatoid arthritis and T1D samples being 
genotyped and imputed independently.
Definition of credible sets.
To define potentially causal variants for each locus, we calculated posterior probabilities 
using the approximate Bayesian factor (ABF)1,2 under the assumption of a single causal 
variant per locus. This framework assumes that the association effect sizes follow a 
distribution of N(0, V) under H0, with V being the squared standard error. Under H1, the 
framework assumes a distribution following N(0,V + W), where W is (ln[1.5]/1.96)2, 
reflecting the prior of observing an odds ratio of 1.5. The ABF for an observed effect size β 
is then calculated as the ratio of P(β∣H0)/P(β∣HA). Using the sum of the ABF for all variants 
in the locus, we calculate the posterior probability (PP) for variant i as:
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PPi =
ABFi
∑k = 0
n ABFk
Following calculation of the posterior probability, we created credible sets by sorting 
associations descending on the basis of their posterior probability and including associations 
such that the sum of posterior probability was >0.95.
Detecting secondary associations.
To determine the presence of multiple independent effects, we performed conditional 
analyses using logistic regression. For each locus with a significant association, we included 
the top-associated variant as a covariate in the null and alternative models and repeated the 
association analysis for that locus. We considered secondary associations significant when P 
< 1.9 × 10−5 (Bonferroni correction for maximum number of variants in significant loci: 
0.05/2,704). We then performed exhaustive pairwise association analyses to test whether the 
primary and secondary associations together provided the strongest pairwise association 
signal given all possible pairs of variants in the locus. We calculated a P value using the 
difference in deviance between the null and alternative models, following a chi-squared 
distribution with two degrees of freedom.
Finally, for loci with two or more independent associations, we assessed whether the risk 
alleles for the associated variants were located on the same haplotypes. We derived 
haplotypes from the phased imputation output (for example, four haplotypes for two 
independent variants). We removed all haplotypes with a frequency of <1% and individuals 
having those haplotypes, and used the haplotype with the highest frequency as a reference. 
We then used logistic regression to test remaining haplotypes for association, assuming a 
log-linear relationship between the number of haplotype copies and disease status. To 
correct for population differences, our null model included covariates as described above.
We also performed fine-mapping using FINEMAP version 1.116, which allows multiple 
independent associations per locus. As input, we used the summary statistics for the 
individual disease association analyses and genotype correlation matrices as linkage 
disequilibrium estimates. Finally, we assessed whether opposite effects between rheumatoid 
arthritis and T1D may cause lower power in the combined analysis by applying Trinculo 
version 0.9615—a method that implements multinomial logistic regression. As covariates for 
this analysis, we used the 20 principal components and indicator variable described above, to 
prevent multicollinearity.
Overlap with eQTLs, H3K4me3 peaks, DNAse-I hypersensitive sites, enhancers, and 
motifs.
To provide functional annotation for the identified variants, we assessed overlap with 
eQTLs, H3K4me3 peaks, DNAse-I hypersensitive sites, promoters, and enhancers. We used 
eQTLs from an RNA sequencing-based eQTL meta-analysis of 2,116 whole blood 
samples54, a study assessing eQTLs in CD4+ T cells from 461 individuals55, a study 
assessing eQTLs in CD4+ and CD8+ cells from 313 individuals56, and tissue-specific eQTLs 
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from the Genotype–Tissue Expression (GTEx) project57. We also included molecular QTLs, 
such as histone QTLs, methylation QTLs, and protein QTLs56,58. For each variant in a 
credible set, we considered a QTL to be overlapping when it was in high linkage 
disequilibrium (R2 > 0.8) with the top QTL for a given gene, methylation probe, histone 
mark, or protein. For calculation of linkage disequilibrium, we used the European 
subpopulation of 1000 Genomes.
For further annotation, we determined the overlap of variants with a posterior probability of 
>0.2 with H3K4me3 peaks, DNAse-I peaks, and ChromHMM59 genome segmentations 
from 12 imputed epigenetic marks from the Roadmap Epigenomics Consortium60, 
consisting of 127 consolidated epigenomes from different cell types. Furthermore, we 
determined whether candidate causal variants affected protein-binding motifs or 
transcription factor binding sites using HaploReg61. Finally, we determined overlap with 
TFBSs using Encyclopedia of DNA Elements project transcription factor chromatin 
immunoprecipitation sequencing62 and determined whether these variants overlapped 
conserved TFBS motifs by defining a 40-bp region around each variant, and using the 
Homer63 software to test all known motifs in vertebrates.
ATAC-Seq time series.
We applied ATAC-Seq64 to measure chromatin accessibility in a time series after 
stimulation. We used a leukopak (30 ml whole blood) from a healthy anonymous donor to 
isolate peripheral blood mononuclear cells using Ficoll tubes, which were stored in 500 μl 
aliquots of 100 × 106 cells in liquid nitrogen. Cells were subsequently thawed and stained 
with anti-biotin microbeads to magnetically select CD4+ Tmem cells. Cells were 
resuspended and transferred to 24-well plates in 3 ml aliquots of 6 × 106 cells and stimulated 
using Dynabeads (Human T-Activator CD3/CD28 for T Cell Expansion and Activation; Life 
Technologies) in a ratio of two cells per bead. Samples of 100,000 cells were taken at 0, 1, 2, 
4, 8, 12, 24, and 48 h after stimulation. Nucleosome isolation and ATAC-Seq open 
chromatin sequencing were performed as described earlier64. Sequenced reads were mapped 
to the hg19 reference genome using BWA-mem. Reads mapping to the mitochondrial 
genome or to multiple genomic locations, and duplicate reads (labeled by Picard 
MarkDuplicates (version 1.128)) were removed, and reads were shifted +4 and −5 bp for the 
reverse and forward strands, respectively. Enrichment for open chromatin was determined by 
calling peaks using MACS version 2.1.0 (ref. 65) (default settings).
Cell lines.
Jurkat and THP-1 cell lines were obtained from the American Type Culture Collection 
(TIB-152 and TIB-202). Jurkat cells were grown in complete Roswell Park Memorial 
Institute (RPMI) (RPMI-1640; Gibco, with 10% decomplemented fetal bovine serum, 
penicillin and streptomycin) and THP-1 cells in complete RPMI supplemented with 2-
mercaptoethanol to a final concentration of 0.05 mM. Both cell lines were grown in a 37°C 
incubator with 5% CO2.
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EMSAs.
EMSAs were performed using the LightShift Chemiluminiscent EMSA Kit (Thermo 
Scientific). Single-stranded oligonucleotides corresponding to 30–32 nucleotide fragments 
of the human genome with the SNP of interest in the middle were purchased from Integrated 
DNA Technologies (Supplementary Table 27) and biotinylated using the Biotin 3′ End 
DNA Labeling Kit (Thermo Scientific). Double-stranded oligonucleotides were generated 
by mixing equal amounts of biotin-labeled (for the probe) or unlabeled (for the competitor) 
complementary oligonucleotides and incubated for 5 min at 95°C and then 1 h at room 
temperature.
Nuclear extract from Jurkat and THP-1 cells was obtained using the NE-PER Nuclear and 
Cytoplasmic Extraction Reagents (Thermo Scientific). Protein extracts were dialyzed using 
a dialysis membrane with a molecular weight cutoff of 12–14 kDa (Spectrum Spectra) 
against 1 l of dialysis buffer (10 mM Tris pH 7.5, 50 mM KCl, 200 mM NaCl, 1 mM 
dithiothreitol, 1 mM phenylmethane sulfonyl fluoride, and 10% glycerol) for 16 h at 4°C 
with slow stirring. Protein inhibitor cocktail (Sigma) was added to a final concentration of 
2.5×. The protein concentration was measured using the Pierce BCA Protein Assay Kit 
(Thermo Scientific).
The standard binding reaction contained 2 μl of 10× Binding Buffer (100 mM Tris pH 7.5, 
500 mM KCl and 10 mM dithiothreitol), 2.5% glycerol, 5 mM MgCl2, 0.05% NP40, 50 ng 
Poly(dI:dC), 20 fmol biotin-labeled probe, and 16 μg nuclear extract in a final volume of 20 
μl. For competition experiments, a 200-fold molar excess (4 pmol) of unlabeled probe was 
added. Variations to these conditions are indicated in the corresponding figure 
(Supplementary Figures 25D, 27B, and 28C).
Binding reactions were incubated at room temperature for 30 min and loaded onto a 6% 
polyacrylamide 0.5× TBE Gel. After sample electrophoresis and transfer to a nylon 
membrane, transferred DNA was crosslinked for 10 min, and the biotinylated probes were 
detected by chemiluminescence followed by film exposure. Original films are presented in 
Supplementary Fig. 29.
Luciferase reporter assay.
The double-stranded oligonucleotide containing the SNP of interest (obtained as described 
above) was cloned downstream from the luciferase gene in the luciferase reporter vector 
pGL3 promoter (Promega). Unlabeled double-stranded oligonucleotides containing the 
corresponding SNPs were amplified with specific primers containing the BamHI restriction 
site obtained from Integrated DNA Technologies (Supplementary Table 28). The PCR was 
carried out in 50 μl reaction volume under the following program: 94 °C for 3 min; 10 cycles 
at 94 °C for 30 s, 60 °C for 40 s, and 68 °C for 30 s; 15 cycles at 94 °C for 30 s, 60 °C for 40 
s, and 68 °C for 30 s; and 72 °C for 10 min (AccuPrime Taq; Invitrogen). Both the PCR 
products and pGL3 promoter vector were digested with BamHI (New England Biolabs) for 
1h at 37 °C, and linearized vector was then dephosphorylated for 30 min at 37 °C with the 
Quick Dephosphorylation kit (New England Biolabs). Digestion products were purified with 
the QIAquick Gel Extraction Kit (Qiagen) from 1.2% agarose gels. Ligation of SNP-
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containing fragments into the pGL3 promoter plasmid was performed in a ratio of 1:50 
(vector:insert) with T4 DNA ligase (New England Biolabs) at 16 °C overnight and 
transformed into JM109 competent cells (Promega). Plasmids from independent colonies 
were isolated using a Wizard Plus SV Minipreps DNA purification system and sequenced 
using RV primer 4 (Promega), selecting those harboring the SNP-construct cloned ‘in sense’ 
in the pGL3 promoter vector for further HighPure plasmid isolation (Invitrogen).
At least three independent transfection experiments for each construct were performed, each 
in duplicate. 2 × 104 Jurkat cells in 0.1 ml of complete RPMI were transfected with 0.8 μg of 
pGL3-Promoter vector along with 0.2 μg of pRL-TK Renilla luciferase vector (Promega) 
using 1.5 μl of Lipofectamine LTX Reagent and 1 μl of PLUS Reagent (both from 
Invitrogen) diluted in Opti-MEM (Gibco). After 16 h of transfection, luciferase activity was 
measured using the Dual-Glo Luciferase Assay System (Promega). Firefly luciferase activity 
was expressed as relative luciferase units (RLU) after correction for Renilla luciferase 
activity to adjust for transfection efficiency. Data were normalized to those cells transfected 
with empty pGL3-Promoter vector.
For the rs117701653 variant at the CD28-CTLA4 locus, we also investigated the luciferase 
signal under stimulatory conditions. We transfected Jurkat cells as described above, and 18 h 
after transfection, cells were left untreated or stimulated with αCD3/αCD28 (0.5 μg αCD3 
coated to the plate and 5 μg ml−1 of soluble α CD28) or phytohemagglutinin (2 μg ml−1). 
Luciferase activity was measured 6 h after stimulation. Four independent experiments were 
performed in duplicate. The results of individual assays are presented in Supplementary 
Table 29.
Statistical analysis of functional studies.
Luciferase activity levels were compared by unpaired two-sided t-test. Error bars represent 
s.d.
Reporting Summary.
Further information on research design is available in the Nature Research Reporting 
Summary linked to this article.
Code availability.
Associated computer code for this manuscript can be found at the following GitHub 
repositories: https://github.com/immunogenomics/harmjan/tree/master/FinemappingPaper 
and https://github.com/immunogenomics/harmjan/tree/master/FinemappingTools.
Data availability
Summary statistics for all variants are available through the following GitHub repository: 
https://github.com/immunogenomics/harmjan/tree/master/RA-T1D-Finemap-SummaryStats. 
Genotype data have been previously published3,4 and are available from Rheumatoid 
Arthritis Consortium International and the Type 1 Diabetes Genetics Consortium upon 
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request. The ATAC-Seq data discussed in this publication have been deposited in the Gene 
Expression Omnibus under accession number GSE116497.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1 ∣. Imputation accuracy and quality of datasets.
Datasets were imputed with different reference panels: the European subpopulation of 1000 
Genomes (EUR), full 1000 Genomes (COSMO), full 1000 Genomes imputed with PBWT 
(COSMO(PBWT)), and HRC. a, We sequenced 799 1-kilobase regions in 568 individuals 
with ImmunoChip genotypes and called 1,854 common (MAF>1%) variants. We calculated 
the imputation accuracy (genomic R2) by correlating imputed genotypes using each 
reference panel with genotypes called from the sequencing experiment. b, INFO scores for 
each reference panel in the rheumatoid arthritis dataset.
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Fig. 2 ∣. Variants in the 95% credible sets of significant loci determined by the Bayesian factor.
a, The inner ring of dots indicates whether the locus has ≤10 variants in the credible set and 
a significant association signal (filled circles). Comb., combined; RA, rheumatoid arthritis. 
The middle ring shows variants in each credible set. Highlighted segments indicate loci with 
a candidate causal variant. The color intensity indicates the posterior probability (PP), gray 
representing a lack of significance. The outer ring shows indel, promoter, and missense 
coding annotation for each variant in the credible set. b, Number of variants in the 95% 
credible sets within significant loci. We narrowed down the list of probable causal variants to 
≤5 in 5 out of 20 significant RA loci, and 10 out of 34 significant T1D loci.
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Fig. 3 ∣. Analysis of the CD28-CTLA4 locus.
a, A regional association plot for the combined analysis (20,787 rheumatoid arthritis or T1D 
cases, and 18,616 unique controls; Methods) shows a single variant (rs3087243) near 
CTLA4 in the credible set. Conditioning on rs30872043 identifies rs117701653 as an 
independent association. Logistic regression −log10[P] values are from a two-sided χ2 test 
(n = 39,403). b, An exhaustive pairwise analysis for rheumatoid arthritis shows that the 
rs3087243 + rs117701653 pair has the strongest association. Logistic regression −log10[P] 
values are from a two-sided χ2 test (n = 27,345). c, Haplotype analysis using rs30872043 
and rs117701653, with the AG haplotype as a reference. The C allele of rs117701653 shows 
the largest decrease in risk for rheumatoid arthritis (RA), and the A allele of rs30872043 
shows the largest decrease in risk for T1D. Logistic regression odds ratios (dots) and 95% 
confidence intervals (bars) are from a two-sided χ2 test (combined n = 39,403; T1D n = 
20,445; RA n = 27,345). d, EMSA with Jurkat nuclear extract using probes containing 
rs117701653 and rs3087243. A representative blot of three independent experiments is 
shown. e, Luciferase assay in Jurkat T cells transfected with pGL3 plasmids containing 
rs117701653. RLUs are normalized to cells transfected with the empty plasmid (pGL3). 
Dots represent independent experiments, each of which was performed in duplicate. Means
±s.d. and two-tailed P values of the grouped comparisons (unpaired t-test) are shown.
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Fig. 4 ∣. Analysis of the MEG3 locus.
a, Regional plot for the MEG3 locus in T1D (9,334 cases, 11,111 controls). We observe two 
variants in the credible set (rs56994090 and the rs34552516 indel). We did not observe 
secondary signals when conditioning on rs56994090. Logistic regression −log10[P] values 
are from a two-sided χ2 test (n = 20,445). b, EMSA with Jurkat nuclear extract using probes 
containing rs354552516 and rs56994090. A representative blot of three independent 
experiments is shown. c, Luciferase assay in Jurkat T cells transfected with pGL3 plasmids 
containing rs34552516. RLUs are normalized to cells transfected with the empty plasmid 
(pGL3). Dots represent independent experiments, each of which was performed in duplicate. 
Means±s.d. and two-tailed P values of the grouped comparisons (unpaired t-test) are shown.
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Fig. 5 ∣. Analysis of the TNFAIP3 locus.
a, Regional plot for the TNFAIP3 locus in rheumatoid arthritis (11,475 cases, 15,870 
controls). The variant with the strongest posterior probability in this locus is rs35926684, a 
G/GA indel. Conditional on rs35926684, we observe a significant secondary association 
with rs58721818. Logistic regression −log10[P] values are from a two-sided χ2 test (n = 
27,345). b, Exhaustive pairwise association analysis in rheumatoid arthritis indicates that 
there are 11 pairs with a lower P value than rs35926684 + rs58721818, although the top-
associated pair (rs69220220 + rs58721818) has an equivalent Pvalue −log10[P] =13.95 
versus 14.21. Logistic regression −log10[P] values are from a two-sided χ2 test (n = 27,345). 
c, Haplotype analysis with rs35926684 + rs58721818 and previously reported variants 
rs6920220 and rs5029937 shows that rs35926684 and the previously reported top variant 
rs6920220 are often located on the same haplotype (GAGC), although a rare haplotype 
exists with only the alternative allele of rs35926684, which causes a similar increase in risk, 
but with a larger confidence interval. Logistic regression odds ratios (dots) and 95% 
confidence intervals (bars) are from a two-sided χ2 test (n = 27,345). RA, rheumatoid 
arthritis d, EMSA with Jurkat nuclear extract using probes containing the G or GA allele of 
rs35926684. A representative blot of three independent experiments is shown. e, Luciferase 
assay in Jurkat T cells transfected with pGL3 plasmids containing rs35926684. RLUs are 
normalized to cells transfected with the empty plasmid (pGL3). Dots represent independent 
experiments, each of which was performed in duplicate. Means±s.d. and two-tailed P values 
of comparisons (unpaired t-test) are shown.
Westra et al. Page 23
Nat Genet. Author manuscript; available in PMC 2019 February 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Westra et al. Page 24
Ta
bl
e 
1 
∣
O
ve
rv
ie
w
 o
f p
ot
en
tia
lly
 c
au
sa
l v
ar
ia
nt
s a
t l
oc
i h
av
in
g 
sig
ni
fic
an
t a
ss
oc
ia
tio
n 
an
d 
95
%
 cr
ed
ib
le
 se
ts 
w
ith
 ≤
10
 v
ar
ia
nt
s
PP
 >
 0
.2
Po
te
nt
ia
lly
ca
u
sa
l
Lo
cu
s
M
ar
ke
r
ge
ne
(s)
Va
ri
an
t
D
ise
as
e
a
ss
o
ci
at
io
n
A
lle
le
s
Pr
ev
io
us
ly
id
en
tif
ie
d
a
s 
to
p
v
a
ri
an
t
O
R
fo
r
R
A
O
R
fo
r
T1
D
PP
 fo
r
R
A
PP
 fo
r
T1
D
PP co
m
bi
ne
d
Va
ri
an
t t
yp
e
R
A
1p
13
.2
PT
PN
22
rs
66
79
67
7
R
A
 +
 T
1D
C,
 A
1.
60
1.
95
0.
48
N
on
co
di
ng
R
A
+T
1D
R
A
 +
 T
1D
rs
24
76
60
1
R
A
 +
 T
1D
G
, A
R
ef
. 8
1.
60
1.
95
0.
52
0.
92
0.
90
p.
A
rg
62
0T
rp
T1
D
1q
32
.1
IL
10
rs
30
24
50
5
T1
D
G
, A
R
ef
. 4
1.
02
0.
85
0.
29
N
on
co
di
ng
T1
D
rs
30
24
49
5
T1
D
C,
 T
1.
02
0.
85
0.
31
N
on
co
di
ng
T1
D
rs
30
24
49
3
T1
D
C,
 A
1.
02
0.
85
0.
32
N
on
co
di
ng
T1
D
2q
24
.2
IF
IH
1
rs
21
11
48
5
T1
D
G
, A
R
ef
. 4
0.
96
0.
85
0.
46
0.
74
N
on
co
di
ng
T1
D
rs
98
49
71
T1
D
A
, G
0.
97
0.
85
0.
31
N
on
co
di
ng
R
A
2q
33
.2
CD
28
 C
TL
A4
rs
55
68
69
54
R
A
G
, A
0.
75
0.
80
0.
27
N
on
co
di
ng
R
A
R
A
rs
11
77
01
65
3
R
A
A
, C
0.
74
0.
79
0.
67
N
on
co
di
ng
T1
D
rs
30
87
24
3
T1
D
; R
A
 (s
ec
on
da
ry)
G
, A
R
ef
s. 
4,
8
0.
90
0.
85
0.
48
0.
91
N
on
co
di
ng
R
A
R
A
3p
14
.3
D
NA
SE
1L
3
rs
35
67
74
70
R
A
G
, A
1.
21
1.
01
0.
82
p.
A
rg
20
6C
ys
T1
D
5q
11
.2
A
N
K
RD
55
rs
10
21
36
92
R
A
 +
 T
1D
T,
 
C
0.
81
0.
90
0.
34
N
on
co
di
ng
rs
11
37
72
54
R
A
 +
 T
1D
A
, A
T
0.
79
0.
89
0.
25
In
de
l
R
A
rs
77
31
62
6
R
A
 +
 T
1D
G
, A
R
ef
. 8
0.
80
0.
90
0.
41
0.
29
N
on
co
di
ng
6q
15
BA
CH
2
rs
10
94
44
79
T1
D
G
, A
1.
12
1.
19
0.
21
N
on
co
di
ng
R
A
rs
72
92
80
38
R
A
 +
 T
1D
G
, A
R
ef
. 4
1.
13
1.
20
0.
37
0.
27
0.
61
N
on
co
di
ng
R
A
rs
69
08
62
6
R
A
 +
 T
1D
G
, T
1.
14
1.
21
0.
29
N
on
co
di
ng
R
A
R
A
6q
23
.3
TN
FA
IP
3
rs
35
92
66
84
R
A
G
A
, G
1.
16
1.
06
0.
24
In
de
l
R
A
9p
13
.3
CC
L2
1
rs
10
97
22
01
R
A
G
, A
1.
12
0.
97
0.
34
N
on
co
di
ng
R
A
rs
28
12
37
8
R
A
A
, G
1.
12
0.
98
0.
36
N
on
co
di
ng
R
A
rs
11
57
49
14
R
A
G
, A
R
ef
. 8
1.
12
0.
97
0.
25
N
on
co
di
ng
T1
D
T1
D
10
p1
5.
1
IL
2R
A
rs
61
83
96
60
T1
D
G
, A
0.
93
0.
64
0.
85
N
on
co
di
ng
R
A
rs
70
67
78
T1
D
C,
 T
R
ef
. 8
1.
09
1.
22
0.
27
0.
89
N
on
co
di
ng
T1
D
10
q2
3.
31
RN
LS
rs
12
41
61
16
T1
D
C,
A
R
ef
. 4
1.
01
0.
85
0.
46
N
on
co
di
ng
T1
D
11
p1
5.
5
IN
S-
IG
F2
rs
38
42
75
3
T1
D
T,
 
G
0.
98
2.
22
0.
73
0.
77
N
on
co
di
ng
T1
D
rs
68
9
T1
D
A
, T
R
ef
. 4
0.
98
2.
21
0.
27
0.
23
N
on
co
di
ng
Nat Genet. Author manuscript; available in PMC 2019 February 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Westra et al. Page 25
PP
 >
 0
.2
Po
te
nt
ia
lly
ca
u
sa
l
Lo
cu
s
M
ar
ke
r
ge
ne
(s)
Va
ri
an
t
D
ise
as
e
a
ss
o
ci
at
io
n
A
lle
le
s
Pr
ev
io
us
ly
id
en
tif
ie
d
a
s 
to
p
v
a
ri
an
t
O
R
fo
r
R
A
O
R
fo
r
T1
D
PP
 fo
r
R
A
PP
 fo
r
T1
D
PP co
m
bi
ne
d
Va
ri
an
t t
yp
e
T1
D
T1
D
12
q2
4.
12
SH
2B
3
rs
31
84
50
4
T1
D
A
, G
1.
04
0.
76
0.
33
0.
45
p.
A
rg
26
2T
rp
T1
D
rs
65
31
78
T1
D
G
, A
R
ef
. 4
1.
04
0.
76
0.
66
0.
54
N
on
co
di
ng
T1
D
13
q3
2.
3
-
rs
95
17
71
2
T1
D
T,
 
C
1.
03
0.
87
0.
34
N
on
co
di
ng
T1
D
rs
95
85
05
6
T1
D
A
, G
R
ef
. 4
0.
96
1.
16
0.
65
N
on
co
di
ng
T1
D
14
q3
2.
2
M
EG
3
rs
56
99
40
90
T1
D
T,
 
C
R
ef
. 4
1.
01
0.
88
0.
44
N
on
co
di
ng
T1
D
T1
D
rs
34
55
25
16
T1
D
TC
, T
1.
00
0.
88
0.
42
In
de
l
T1
D
15
q2
5.
1
CT
SH
rs
34
84
33
03
R
A
A
, G
0.
98
0.
78
0.
45
N
on
co
di
ng
R
A
rs
34
59
34
39
R
A
G
, A
R
ef
. 4
0.
99
0.
77
0.
51
N
on
co
di
ng
R
A
+T
1D
R
A
+T
1D
19
p1
3.
2
TY
K
2
rs
34
53
64
43
R
A
 +
 T
1D
C,
 G
R
ef
s. 
4,
 
8
0.
71
0.
64
0.
41
1.
00
1.
00
p.
Pr
o1
10
4A
la
R
A
rs
35
01
88
00
R
A
(se
co
nd
ary
)
G
, A
p.
A
la
92
8V
al
R
A
T1
D
rs
12
72
03
56
Co
m
bi
ne
d(s
ec
on
da
ry)
A
, C
R
ef
. 4
p.
Ile
68
4S
er
R
A
rs
45
52
46
32
R
A
C,
 A
0.
54
0.
69
0.
53
N
on
co
di
ng
T1
D
20
p1
3
SI
RP
G
rs
60
43
40
5
T1
D
T,
 
C
1.
02
1.
15
0.
26
N
on
co
di
ng
T1
D
rs
61
10
69
7
T1
D
T,
 
C
1.
02
1.
15
0.
23
N
on
co
di
ng
T1
D
T1
D
rs
60
43
40
9
T1
D
A
, G
R
ef
. 4
1.
02
0.
87
0.
24
p.
Va
l2
63
A
la
T1
D
21
q2
2.
3
U
BA
SH
3A
rs
80
05
44
10
T1
D
A
, G
1.
06
1.
16
0.
41
0.
59
N
on
co
di
ng
T1
D
rs
11
20
32
03
T1
D
G
, A
1.
05
1.
16
0.
39
N
on
co
di
ng
T1
D
22
q1
2.
3
C1
QT
NF
6
rs
22
95
33
T1
D
A
, C
R
ef
. 4
0.
99
1.
15
0.
23
N
on
co
di
ng
W
e 
de
cl
ar
e 
va
ria
nt
s a
t t
he
se
 lo
ci
 a
s p
ot
en
tia
lly
 c
au
sa
l w
he
n 
th
ey
 a
re
 c
od
in
g 
an
d 
ha
v
e 
a 
po
ste
rio
r p
ro
ba
bi
lit
y 
(P
P)
 of
 >0
.2,
 or
 w
he
n t
he
y 
ar
e 
no
nc
od
in
g,
 h
av
e 
a 
PP
 o
f >
0.
2,
 a
nd
 h
av
e 
fu
nc
tio
na
l e
v
id
en
ce
 fr
om
 
th
e 
EM
SA
 a
nd
 lu
ci
fe
ra
se
 a
ss
ay
s. 
Lo
gi
sti
c 
re
gr
es
sio
n 
od
ds
 ra
tio
 (O
R)
 va
lu
es
 a
re
 fr
om
 a
 tw
o
-s
id
ed
 χ2
 
te
st
 (c
om
bin
ed
, n
 
=
 3
9,
40
3;
 T
1D
, n
 
=
 2
0,
44
5;
 rh
eu
m
at
oi
d 
ar
th
rit
is 
(R
A)
, n
 
=
 2
7,
34
5).
Nat Genet. Author manuscript; available in PMC 2019 February 06.
